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Opinion statement
Intravenous alteplase or tissue plasminogen activator (tPA) has been the standard of
care with proven efficacy for acute ischemic stroke for over a decade. Despite this, only
a small fraction of potentially eligible stroke patients receive this medication. There
seems to be a fear among practitioners of legal repercussions as a result of an increased
risk of intracerebral hemorrhage due to tPA. This review of legal cases involving tPA
will show that instead, physicians are often found liable as a result of not treating with
tPA.
Introduction
Intravenous tissue plasminogen activator (tPA) has been
approved by the US Food and Drug Administration
(FDA) for the treatment of acute ischemic stroke within
3 h of symptom onset since 1996. Despite multiple ran-
domized controlled trials and statistical evidence sup-
porting its efficacy over placebo, there is still some
reluctance to use the drug because of the increased risk
of hemorrhage [1, 2•]. However, these risks have been
highly exaggerated in the past and the true benefits have
been grossly underestimated [2•]. Given the dissension
among trained medical professionals and the variations
in data interpretation, it is not surprising that there are
current concerns over potential litigation involving the
use and non-use of the drug.
Pathophysiology
Alteplase was the first recombinant tissue-type plas-
minogen activator that is identical to intrinsic human
tPA. In the body, tissue-type plasminogen activator is
synthesized and released by cells of the vascular endo-
thelium and is responsible for most of the body’s nat-
ural efforts to prevent excessive thrombus formation
or dissolve those that are no longer needed [3].
Alteplase is fibrin specific, with a plasma half-life of
3 to 6 min and should hypothetically be effective only
at the surface of a fibrin clot. However, despite greater
fibrin affinity than any other thrombolytic agent, a
general systemic lytic state can occur with the potential
for systemic bleeding [4].
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Treatment
The use of tPA in acute ischemic stroke
& IV tPA is the only FDA-approved therapy for acute ischemic stroke.
Recombinant tPA was initially developed in the mid 1980s as a
potential treatment for acute coronary artery occlusion. Studies on
the use of thrombolytic therapy in acute strokes have been conducted
since the 1950s [5]. Although other thrombolytic agents such as
streptokinase have been complicated by increased rates of hemor-
rhage, they provided the basis for more sophisticated randomized
trials [6].
& Given its greater fibrin specificity, recombinant tPA was favored in
studies during the 1990s because of its safety as compared with other
thrombolytic agents.
& Earlier work from past decades suggested better outcomes in patients
who were treated soon after symptom onset [7, 8]. Open-labeled
dose-escalation studies showed that there was a statistical correlation
between the incidence of symptomatic intracerebral hemorrhage
(ICH) and total dose of drug administered [9].
& In 1995, the results of the National Institute of Neurological Disor-
ders and Stroke (NINDS) stroke trial were published. This was a two-
part, randomized, double-blind trial of intravenous (IV) tPA at a
dose of 0.9 mg/kg versus placebo in patients with stroke symptoms
within 3 h of onset. It showed that patients who received IV tPA
within 3 h of their stroke onset were at least 30% more likely to have
little or no disability at 3 months, with an odds ratio for favorable
outcome of 1.7 [10]. In an independent 2004 analysis of original
data from this trial using an independent panel comprised of neu-
rologists and emergency room physicians who were experts in the
field of stroke to assess outcomes, Saver [11] showed that the average
number needed to treat for one patient to have a better outcome,
defined as a change in the modified Rankin score (mRS) of 1 or
more, is 3.1. Therefore, as judged by these experts, for every 100
patients treated with tPA, 32 will have a better final outcome because
of the treatment [11].
& The European Cooperative Acute Study (ECASS III) widened the
potential window for treatment from 3 h to 4.5 h with their pub-
lished findings in 2008 showing that there was still a more favorable
outcome with patients who were treated with IV tPA compared to
placebo with an odds ratio of 1.34 [12]. The patient selection was
slightly different from the NINDS trials in that ECASS III excluded
patients older than 80 years of age, had a combination of prior stroke
and diabetes, and National Institute of Health Stroke Scale score
greater than 25 [12]. Also, this trial independently confirmed in a
placebo-controlled study that tPA is an effective treatment, a fact that
was initially established by the original NINDS study [10].
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& Although ECASS III showed some benefits to patients treated in the
3- to 4.5-h time period, patients who were treated closer to the time
of stroke onset tended to have better outcomes, and it is still only
FDA approved for use within 3 h of onset. In a 2010 pooled analysis
of the eight major randomized placebo-controlled trials of tPA and
acute ischemic stroke, investigators showed that the odds of a fa-
vorable outcome at 3 months decreased as the onset to time to
treatment (OTT) number increased and the odds of mortality in-
creased with the OTT. Adjusted odds of favorable outcomes in
patients treated with tPA were 2.55 for patients treated from 0 to
90 min, 1.64 for those between 91 to 180 min, 1.34 for 181 to
270 min and 1.22 for 271 to 360 min. Adjusted odds of mortality
were, respectively, 0.78, 1.13, 1.22, and 1.49 for the same time
ranges, indicating that patients had an increased chance of better
outcome, including survival, if they were treated early [13].
Bleeding risks
& Despite numerous studies and analyses showing the benefits of tPA
and reviews of the legal literature suggesting that physicians are more
liable to lawsuits for failure to use tPA, there is still reluctance among
providers, with most citing the concern for bleeding risks [1]. The
NINDS trials showed a risk of ICH of 6.4% in patients who were
treated with tPA compared to 0.6% in the placebo group [10].
& In 2007, Saver [2•] again analyzed the original data from the NINDS
stroke studies and found that when compared to placebo, the
patients in the treatment group who experienced symptomatic sICH
were older, had more severe stroke symptoms, higher serum glucose,
and more likely to have mass effect on their pretreatment CT scan.
The calculated number needed to harm for one patient to have a
severely disabling or deadly outcome (defined as a mRS 94) due to
their tPA-associated sICH was 126, or approximately one of every
100 patients who experience sICH in the setting of tPA treatment
[2•].
The issue of standard of care
& In 1996, the FDA approved the use of tPA in acute ischemic stroke,
and in August of 2000 the American Heart Association upgraded its
recommendation from Class IIB (optional) to Class I (definite rec-
ommendation). Multiple national organizations, most of them
comprised of emergency room physicians, have challenged this
change, arguing that more evidence is needed before it could be the
standard of care [14].
& Such variations in clinical practice suggest that, currently, there may
be no universally accepted standard when it comes to the treatment
of acute ischemic stroke. Given more studies proving the efficacy of
tPA as an effective treatment in acute ischemic stroke and the emer-
gence of stroke centers, this is rapidly changing.
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& In 2000, a prospective analysis of 29 Cleveland-area hospitals
showed that only 2% of patients admitted for acute ischemic stroke
from July of 1997 to June of 1998 received tPA. Seventeen percent of
these patients presented within 3 h of symptom onset, and of these
patients only 10.4% received treatment. The rate of sICH was 15.7%,
much higher than the NINDS study, but in half of the patients
treated there was a deviation to the protocol established by the study
[15]. Numbers similar to these have been reported in other studies,
suggesting that the majority of patients who meet criteria for tPA
treatment do not receive therapy. Katzan et al. [16] published an
update a few years later after a stroke quality improvement program
was implemented in nine of the Cleveland-area hospitals and
showed 18.8% of patients who presented within 3 h received tPA
treatment. The rate of sICH in these patients was 6.4%, similar to the
original NINDS study, and protocol violations decreased to 19%
[16]. Although these numbers may still appear elevated, they imply
that closer adherence to the original study criteria decreases the rate
of adverse effects.
Medico-legal cases
& Medico-legal concerns are a major barrier to treating stroke patients
with tPA. A recent empirical study of trial court cases involving tPA
and ischemic stroke showed that most cases involved emergency
physicians, and that liability is most often associated with failure to
treat with IV tPA, rather than adverse events associated with its use
[17••].
& The definition of medical malpractice is an act or omission by a
health care provider that deviates or fails to conform to the
accepted standards of practice in the medical community that
subsequently results in injury to the patient. In order to prove
such negligence and achieve a successful malpractice claim, a
plaintiff has to establish the following four elements:
1. a duty was owed (an element that exists whenever a hospital or
health care provider undertakes care or treatment of a patient)
2. a duty was breached (the provider failed to conform or deviated
from the appropriate standard of care)
3. the breach caused an injury
4. the injury led to damages (the foundation for a suit, without
which, there is no basis for a claim, regardless of whether the
medical provider was negligent) [18].
& A 2006 review by Weintraub [19] depicted several anecdotal cases to
illustrate the variation in types of malpractice claims, from failure to
treat to adverse outcomes from treatment, and illustrated the difficulties
of defining negligence without an accepted standard of care. He argued
that given the continual evolution of accepted stroke therapy, the jury
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could not always distinguish medical malpractice from medical maloc-
currence [19]. However, although anecdotes might give some insight to
the trend in public perception, they are merely descriptive and do not
offer measurable variables that could be use to establish any meaningful
standard or code of conduct. Baumbauer et al. [1] hypothesized that the
reason physicians may not administer IV tPA is their fear of potential
lawsuits for medical malpractice. To evaluate their theory, they queried
the LexisNexis Academic database for cases involving physicians and the
use of tPA in stroke. Most cases ended with a settlement and, therefore,
were not publicly available, and the database contains mostly appellate
level decisions. However, they were able to identify seven cases with
final decisions. In all cases, claims were filed for the failure to administer
tPA, but only one of these cases favored the plaintiff [1].
& In a 2008 review of lawsuits involving tPA, Liang and Zivin [17••]
identified 33 cases that involved tPA and stroke. More than half of these
cases involved emergency room physicians and less than 20% involved
neurologists. In every case in which a neurologist was a defendant, the
emergency physician was also named. In about two thirds of the cases,
plaintiffs stated a failure or delay in diagnosis of stroke. In 87.9% of the
cases, patients claimed there was a failure to treat with IV tPA, whereas
only 9.1% cited that the use of the drug caused their injury. In 12 of the
33 cases, the plaintiffs were given positive verdicts, with 2 of the 12
rewarded for injury from the use of the drug and the majority for failure
to treat with tPA. With the increasing use and expansion of the thera-
peutic time window, physicians are interested more than ever about the
potential legal ramifications [17••].
& In regard to failure to treat, a plaintiff has the burden of not only
proving that there was a deviation from the standard of care, but also
that the diversion caused direct injury. Various jurisdictions may rule
differently on whether to use this standard, or they may require that tPA
show benefit in more than 50% of patients without including the
placebo responders. In a 2008 reanalysis of the NINDS data, Liang et al.
[20•] used proportionate pairs (one treated with placebo, the other with
tPA) and placed patients in all possible combinations using the
Wilcoxon test. From these pairs, they determined which of the two had
better outcomes, described as a better mRS score at 90 days compared to
baseline prior to treatment. In the case of a tie between patients, a larger
change in the NIHSS was considered the superior outcome. They
reported that the probability that IV tPA was superior was 57.3%.
Although this number may have included patients who would have
improved spontaneously without tPA, it is reasonable to include them
because it would be impossible for clinicians to identify these patients
prior to treatment [20•].
& Traditionally, legal causation is demonstrated by showing that there was
a greater than 50% chance that the failure to give the drug caused the
patient injury, but some courts will allow a plaintiff to recover for the
loss of opportunity for a better outcome [21, 22]. In a search of state and
federal cases Thiess et al. [23] identified 20 trial court and six appellate
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cases that involved suits over the nonuse of IV tPA for patients with a
stroke, and none for injury caused allegedly by the drug. In 14 of 20
cases, the verdict was for the defendant [23].
& The preponderance of evidence suggests that IV tPA is not only effective,
but it is safe. Physicians caring for stroke patients should not deny its use
in appropriate patients for fear of being sued. More often, it seems
verdicts against the defendant arise in cases where IV TPA was not used
or where there were deviations from the standard of care. However, the
legal landscape is now rapidly changing and as more cases are adjudi-
cated, the conclusions we make are quickly changing.
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